Sunitinib Malate Provides Additional Survival and Value for Money as a Second Line Treatment for Metastatic Renal Cell Carcinoma (mRCC) - an evaluation using bayesian approach
- Kellokumpu-Lehtinen, P. (Contributor)
Activity: Talk or presentation › Conference presentation